Keywords: Hyperion, Ravicti, Urea cycle disorders, USA, FDA, Seattle Genetics, Adcetris, Health Canada, Hodgkin lymphoma

Regulatory news for Hyperion's Ravicti and Seattle Genetics' Adcetris

Article | 04 February 2013

The US Food and Drug Administration on Friday approved Hyperion Therapeutics’ (Nasdaq: HPTX) Ravicti (glycerol phenylbutyrate) for the chronic ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Hyperion Therapeutics

Seattle Genetics

Go to company listing

Related Drugs

Ravicti

Adcetris

Go to drug listing